MMR Vaccine: Measles, Mumps, Rubella - Schedule, Efficacy, and Safety

MMR vaccine is a live-attenuated combination vaccine protecting against three viral diseases.

Components

  • Measles: Morbillivirus; fever, cough, coryza, conjunctivitis, Koplik spots, maculopapular rash. Complications: pneumonia, encephalitis, SSPE, immune amnesia.
  • Mumps: Paramyxovirus; parotitis, orchitis, meningitis, pancreatitis, deafness.
  • Rubella: Togavirus; mild rash, lymphadenopathy, arthralgia. Teratogenic: congenital rubella syndrome (cataracts, deafness, heart defects, ID).

Schedule (CDC/ACIP)

  • Dose 1: 12–15 months
  • Dose 2: 4–6 years (school entry)
  • Catch-up: ≥4 weeks between doses; teens/adults without evidence of immunity: 2 doses ≥28 days apart.
  • Travel: Infants 6–11 mo: 1 dose (does not count toward series); revaccinate at 12 mo.

Effectiveness

  • Measles: 93% (1 dose), 97% (2 doses)
  • Mumps: 78% (1), 88% (2) — waning immunity drives outbreaks
  • Rubella: 97% (1 dose)

Contraindications & Precautions

  • Severe immunodeficiency (HIV CD4 <200, chemo, high-dose steroids)
  • Pregnancy (avoid conception 1 month post-vaccine)
  • Anaphylaxis to neomycin/gelatin or prior dose
  • Recent blood products (wait 3–11 months)

Safety

  • Fever (5–15%), rash (5%), febrile seizures (1/3000–4000), transient thrombocytopenia (1/30,000).
  • No link to autism (original Wakefield study retracted; >20 large studies confirm).

Public Health Impact

Measles eliminated in US (2000); importations cause outbreaks in under-vaccinated communities. High coverage (>95%) maintains herd immunity.

Medical Billing - Related Articles